Cardiovascular magnetic resonance in heart failure

Current Cardiology Reports

Volumn 13, Issue 3, 2011, Pages 210-219

  Karamitsos, Theodoros D ^a   Neubauer, Stefan ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Cardiomyopathies; Cardiovascular imaging; Coronary artery disease; Diagnosis; Ischemia; Prognosis

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT;

CARDIAC ALLOGRAFT VASCULOPATHY; CARDIAC GRAFT REJECTION; CARDIOTOXICITY; CARDIOVASCULAR MAGNETIC RESONANCE; CONGENITAL HEART DISEASE; CONGESTIVE CARDIOMYOPATHY; CONSTRICTIVE PERICARDITIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; ECHOCARDIOGRAPHY; FABRY DISEASE; FUNCTIONAL MORPHOLOGY; HEART AMYLOIDOSIS; HEART ARRHYTHMIA; HEART FAILURE; HEART HEMOSIDEROSIS; HEART MUSCLE ISCHEMIA; HEART TRANSPLANTATION; HEART VALVE REGURGITATION; HEART VENTRICLE FUNCTION; HEMODYNAMIC MONITORING; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; INTERMETHOD COMPARISON; ISCHEMIC CARDIOMYOPATHY; MYOCARDITIS; PREDICTIVE VALUE; RADIOCARDIOGRAPHY; REVIEW; SENSITIVITY AND SPECIFICITY; SILENT MYOCARDIAL INFARCTION; SYSTOLIC DYSFUNCTION; VALVULAR HEART DISEASE;

CARDIOMYOPATHIES; HEART FAILURE; HUMANS; MAGNETIC RESONANCE IMAGING; MYOCARDIAL ISCHEMIA; VENTRICULAR FUNCTION;

EID: 79955926941     PISSN: 15233782     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11886-011-0177-2     Document Type: Review

References (73)

1. Lloyd-Jones D, Adams RJ, Brown TM, et al. Heart disease and stroke statistics-2010 update: a report from the American heart association. Circulation. 2010;121:e46-e215.
2. Karamitsos TD, Francis JM, Myerson S, et al. The role of cardiovascular magnetic resonance imaging in heart failure. J Am Coll Cardiol. 2009;54:1407-24.
3. Hudsmith LE, Neubauer S. Magnetic resonance spectroscopy in myocardial disease. JACC Cardiovasc Imaging. 2009;2:87-96.
4. Kribben A, Witzke O, Hillen U, et al. Nephrogenic systemic fibrosis: pathogenesis, diagnosis, and therapy. J Am Coll Cardiol. 2009;53:1621-8.
5. Karamitsos TD, Hudsmith LE, Selvanayagam JB, et al. Operator induced variability in left ventricular measurements with cardiovascular magnetic resonance is improved after training. J Cardiovasc Magn Reson. 2007;9:777-83. (Pubitemid 47463903)
6. Christiansen JP, Karamitsos TD, Myerson SG. Assessment of valvular heart disease by cardiovascular magnetic resonance imaging: a review. Heart Lung Circ. 2011;20:73-82.
7. Abdel-Aty H, Simonetti O, Friedrich MG. T2-weighted cardiovascular magnetic resonance imaging. J Magn Reson Imaging. 2007;26:452-9. (Pubitemid 350194566)
8. Piechnik SK, Ferreira VM, Dall'armellina E, et al. Shortened modified look-locker inversion recovery (shmolli) for clinical myocardial t1-mapping at 1.5 and 3 t within a 9 heartbeat breathhold. J Cardiovasc Magn Reson. 2010;12:69.
9. Giri S, Chung YC, Merchant A, et al. T2 quantification for improved detection of myocardial edema. J Cardiovasc Magn Reson. 2009;11:56.
10. Kim RJ, Fieno DS, Parrish TB, et al. Relationship of MRI delayed contrast enhancement to irreversible injury, infarct age, and contractile function. Circulation. 1999;100:1992-2002. (Pubitemid 29529292)
11. Nagel E, Lehmkuhl HB, Bocksch W, et al. Noninvasive diagnosis of ischemia-induced wall motion abnormalities with the use of high-dose dobutamine stress MRI: comparison with dobutamine stress echocardiography. Circulation. 1999;99:763-70. (Pubitemid 29083016)
12. Christiansen JP, Karamitsos TD, Myerson SG, et al. Stress perfusion imaging using cardiovascular magnetic resonance: a review. Heart Lung Circ. 2010;19:697-705.
13. Karamitsos TD, Ntusi NA, Francis JM, et al. Feasibility and safety of high-dose adenosine perfusion cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2010;12:66.
14. Karamitsos TD, Arnold JR, Pegg TJ, et al. Tolerance and safety of adenosine stress perfusion cardiovascular magnetic resonance imaging in patients with severe coronary artery disease. Int J Cardiovasc Imaging. 2009;25:277-83.
15. Leyva F. Cardiac resynchronisation therapy guided by cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2010;12:64.
16. Ypenburg C, Schalij MJ, Bleeker GB, et al. Impact of viability and scar tissue on response to cardiac resynchronization therapy in ischaemic heart failure patients. Eur Heart J. 2007;28:33-41. (Pubitemid 46134955)
17. White JA, Yee R, Yuan X, et al. Delayed enhancement magnetic resonance imaging predicts response to cardiac resynchronization therapy in patients with intraventricular dyssynchrony. J Am Coll Cardiol. 2006;48:1953-60. (Pubitemid 44738444)
18. Wagner A, Mahrholdt H, Holly TA, et al. Contrast-enhanced MRI and routine single photon emission computed tomography (spect) perfusion imaging for detection of subendocardial myocardial infarcts: an imaging study. Lancet. 2003;361:374-9. (Pubitemid 36164969)
19. Kwong RY, Chan AK, Brown KA, et al. Impact of unrecognized myocardial scar detected by cardiac magnetic resonance imaging on event-free survival in patients presenting with signs or symptoms of coronary artery disease. Circulation. 2006;113:2733-43. (Pubitemid 43947991)
20. Kwong RY, Sattar H, Wu H, et al. Incidence and prognostic implication of unrecognized myocardial scar characterized by cardiac magnetic resonance in diabetic patients without clinical evidence of myocardial infarction. Circulation. 2008;118:1011-20.
21. Kim RJ, Wu E, Rafael A, et al. The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction. N Engl J Med. 2000;343:1445-53.
22. Selvanayagam JB, Kardos A, Francis JM, et al. Value of delayed-enhancement cardiovascular magnetic resonance imaging in predicting myocardial viability after surgical revascularization. Circulation. 2004;110:1535-41. (Pubitemid 39297973)
23. Wellnhofer E, Olariu A, Klein C, et al. Magnetic resonance low-dose dobutamine test is superior to scar quantification for the prediction of functional recovery. Circulation. 2004;109:2172-4. (Pubitemid 38625392)
24. Pegg TJ, Selvanayagam JB, Jennifer J, et al. Prediction of global left ventricular functional recovery in patients with heart failure undergoing surgical revascularisation, based on late gadolinium enhancement cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2010;12:56. This is an important paper that describes the ability of LGE to predict not only regional but also global recovery of function post revascularization.
25. Yan AT, Shayne AJ, Brown KA, et al. Characterization of the periinfarct zone by contrast-enhanced cardiac magnetic resonance imaging is a powerful predictor of post-myocardial infarction mortality. Circulation. 2006;114:32-9. (Pubitemid 44305272)
26. Roes SD, Borleffs CJ, van der Geest RJ, et al. Infarct tissue heterogeneity assessed with contrast-enhanced MRI predicts spontaneous ventricular arrhythmia in patients with ischemic cardiomyopathy and implantable cardioverter-defibrillator. Circ Cardiovasc Imaging. 2009;2:183-90.
27. Rahimi K, Banning AP, Cheng AS, et al. Prognostic value of coronary revascularisation-related myocardial injury: a cardiac magnetic resonance imaging study. Heart. 2009;95:1937-43. This paper describes the prognostic value of procedural myocardial injury in patients undergoing percutaneous coronary intervention or coronary artery bypass grafting.
28. Kelle S, Roes SD, Klein C, et al. Prognostic value of myocardial infarct size and contractile reserve using magnetic resonance imaging. J Am Coll Cardiol. 2009;54:1770-7.
29. Aletras AH, Tilak GS, Natanzon A, et al. Retrospective determination of the area at risk for reperfused acute myocardial infarction with t2-weighted cardiac magnetic resonance imaging: histopathological and displacement encoding with stimulated echoes (dense) functional validations. Circulation. 2006;113:1865-70. (Pubitemid 43739398)
30. Dall'Armellina E, Karamitsos TD, Neubauer S, Choudhury RP. Cmr for characterization of the myocardium in acute coronary syndromes. Nat Rev Cardiol. 2010;7:624-36.
31. Hamon M, Fau G, Nee G, et al. Meta-analysis of the diagnostic performance of stress perfusion cardiovascular magnetic resonance for detection of coronary artery disease. J Cardiovasc Magn Reson. 2010;12:29.
32. Schwitter J, Wacker CM, van Rossum AC, et al. Mr-impact: comparison of perfusion-cardiac magnetic resonance with single-photon emission computed tomography for the detection of coronary artery disease in a multicentre, multivendor, randomized trial. Eur Heart J. 2008;29:480-9. (Pubitemid 351264187)
33. Cheng AS, Pegg TJ, Karamitsos TD, et al. Cardiovascular magnetic resonance perfusion imaging at 3-tesla for the detection of coronary artery disease: a comparison with 1.5-tesla. J Am Coll Cardiol. 2007;49:2440-9. (Pubitemid 46962268)
34. Bodi V, Sanchis J, Lopez-Lereu MP, et al. Prognostic value of dipyridamole stress cardiovascular magnetic resonance imaging in patients with known or suspected coronary artery disease. J Am Coll Cardiol. 2007;50:1174-9. (Pubitemid 47375015)
35. Jahnke C, Nagel E, Gebker R, et al. Prognostic value of cardiac magnetic resonance stress tests: adenosine stress perfusion and dobutamine stress wall motion imaging. Circulation. 2007;115:1769-76. (Pubitemid 46648614)
36. Korosoglou G, Elhmidi Y, Steen H, et al. Prognostic value of high-dose dobutamine stress magnetic resonance imaging in 1, 493 consecutive patients: assessment of myocardial wall motion and perfusion. J Am Coll Cardiol. 2010;56:1225-34.
37. Kato S, Kitagawa K, Ishida N, et al. Assessment of coronary artery disease using magnetic resonance coronary angiography: a national multicenter trial. J Am Coll Cardiol. 2010;56:983-91. This is a Japanese multicenter study describing the utility of stateof- the-art three-dimensional whole-heart coronary angiography.
38. Schuetz GM, Zacharopoulou NM, Schlattmann P, Dewey M. Meta-analysis: noninvasive coronary angiography using computed tomography versus magnetic resonance imaging. Ann Intern Med. 2010;152:167-77.
39. Bluemke DA, Achenbach S, Budoff M, et al. Noninvasive coronary artery imaging: Magnetic resonance angiography and multidetector computed tomography angiography: a scientific statement from the American heart association committee on cardiovascular imaging and intervention of the council on cardiovascular radiology and intervention, and the councils on clinical cardiology and cardiovascular disease in the young. Circulation. 2008;118:586-606.
40. Spuentrup E, Ruhl KM, Botnar RM, et al. Molecular magnetic resonance imaging of myocardial perfusion with ep-3600, a collagen-specific contrast agent: initial feasibility study in a swine model. Circulation. 2009;119:1768-75.
41. Karamitsos TD, Leccisotti L, Arnold JR, et al. Relationship between regional myocardial oxygenation and perfusion in patients with coronary artery disease: insights from cardiovascular magnetic resonance and positron emission tomography. Circ Cardiovasc Imaging. 2010;3:32-40. This is a validation study of the BOLD CMR technique at 3 T against positron emission tomography in normal volunteers and patients with coronary artery disease.
42. McAteer MA, Akhtar AM, von Zur Muhlen C, Choudhury RP. An approach to molecular imaging of atherosclerosis, thrombosis, and vascular inflammation using microparticles of iron oxide. Atherosclerosis. 2010;209:18-27.
43. McCrohon JA, Moon JC, Prasad SK, et al. Differentiation of heart failure related to dilated cardiomyopathy and coronary artery disease using gadolinium-enhanced cardiovascular magnetic resonance. Circulation. 2003;108:54-9. (Pubitemid 36859020)
44. Roberts WC, Siegel RJ, McManus BM. Idiopathic dilated cardiomyopathy: analysis of 152 necropsy patients. Am J Cardiol. 1987;60:1340-55.
45. Assomull RG, Prasad SK, Lyne J, et al. Cardiovascular magnetic resonance, fibrosis, and prognosis in dilated cardiomyopathy. J Am Coll Cardiol. 2006;48:1977-85. (Pubitemid 44738448)
46. Petersen SE, Jerosch-Herold M, Hudsmith LE, et al. Evidence for microvascular dysfunction in hypertrophic cardiomyopathy: new insights from multiparametric magnetic resonance imaging. Circulation. 2007;115:2418-25. (Pubitemid 46717964)
47. Maron MS. The current and emerging role of cardiovascular magnetic resonance imaging in hypertrophic cardiomyopathy. J Cardiovasc Transl Res. 2009;2:415-25.
48. Adabag AS, Maron BJ, Appelbaum E, et al. Occurrence and frequency of arrhythmias in hypertrophic cardiomyopathy in relation to delayed enhancement on cardiovascular magnetic resonance. J Am Coll Cardiol. 2008;51:1369-74. (Pubitemid 351443083)
49. Papavassiliu T, Germans T, Fluchter S, et al. Cmr findings in patients with hypertrophic cardiomyopathy and atrial fibrillation. J Cardiovasc Magn Reson. 2009;11:34.
50. Bruder O, Wagner A, Jensen CJ, et al. Myocardial scar visualized by cardiovascular magnetic resonance imaging predicts major adverse events in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. 2010;56:875-87. This is a study that describes the independent prognostic value of LGE in patients with HCM.
51. O'Hanlon R, Grasso A, Roughton M, et al. Prognostic significance of myocardial fibrosis in hypertrophic cardiomyopathy. J Am Coll Cardiol. 2010;56:867-74. This study demonstrates the independent prognostic value of LGE in patients with HCM.
52. Marcus FI, McKenna WJ, Sherrill D, et al. Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia: proposed modification of the task force criteria. Circulation. 2010;121:1533-41.
53. Jain A, Tandri H, Calkins H, Bluemke DA. Role of cardiovascular magnetic resonance imaging in arrhythmogenic right ventricular dysplasia. J Cardiovasc Magn Reson. 2008;10:32.
54. Sen-Chowdhry S, Syrris P, Prasad SK, et al. Left-dominant arrhythmogenic cardiomyopathy: an under-recognized clinical entity. J Am Coll Cardiol. 2008;52:2175-87.
55. Anderson LJ, Holden S, Davis B, et al. Cardiovascular t2-star (t2*) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J. 2001;22:2171-9. (Pubitemid 33139463)
56. Kirk P, Roughton M, Porter JB, et al. Cardiac t2* magnetic resonance for prediction of cardiac complications in thalassemia major. Circulation. 2009;120:1961-8. This is a study that demonstrates the ability of cardiac T2* CMR to predict HF development in patients with thalassemia major.
57. Abdel-Aty H, Boye P, Zagrosek A, et al. Diagnostic performance of cardiovascular magnetic resonance in patients with suspected acute myocarditis: comparison of different approaches. J Am Coll Cardiol. 2005;45:1815-22. (Pubitemid 40779862)
58. Friedrich MG, Sechtem U, Schulz-Menger J, et al. Cardiovascular magnetic resonance in myocarditis: a jacc white paper. J Am Coll Cardiol. 2009;53:1475-87. This is a paper that describes the comprehensive evaluation of patients with myocarditis using CMR.
59. Mahrholdt H, Wagner A, Deluigi CC, et al. Presentation, patterns of myocardial damage, and clinical course of viral myocarditis. Circulation. 2006;114:1581-90. (Pubitemid 44547428)
60. Mahrholdt H, Goedecke C, Wagner A, et al. Cardiovascular magnetic resonance assessment of human myocarditis: a comparison to histology and molecular pathology. Circulation. 2004;109:1250-8. (Pubitemid 38379570)
61. Maceira AM, Joshi J, Prasad SK, et al. Cardiovascular magnetic resonance in cardiac amyloidosis. Circulation. 2005;111:186-93. (Pubitemid 40139730)
62. Syed IS, Glockner JF, Feng D, et al. Role of cardiac magnetic resonance imaging in the detection of cardiac amyloidosis. JACC Cardiovasc Imaging. 2010;3:155-64.
63. Austin BA, Tang WH, Rodriguez ER, et al. Delayed hyper-enhancement magnetic resonance imaging provides incremental diagnostic and prognostic utility in suspected cardiac amyloidosis. JACC Cardiovasc Imaging. 2009;2:1369-77.
64. Patel MR, Cawley PJ, Heitner JF, et al. Detection of myocardial damage in patients with sarcoidosis. Circulation. 2009;120:1969-77.
65. De Cobelli F, Esposito A, Belloni E, et al. Delayed-enhanced cardiac MRI for differentiation of fabry's disease from symmetric hypertrophic cardiomyopathy. AJR Am J Roentgenol. 2009;192:W97-W102.
66. Petersen SE, Selvanayagam JB, Wiesmann F, et al. Left ventricular non-compaction: Insights from cardiovascular magnetic resonance imaging. J Am Coll Cardiol. 2005;46:101-5. (Pubitemid 40905136)
67. Karamitsos TD, Bull S, Spyrou N, et al. Tako-tsubo cardiomyopathy presenting with features of left ventricular non-compaction. Int J Cardiol. 2008;128:e34-6.
68. Ariyarajah V, Jassal DS, Kirkpatrick I, Kwong RY. The utility of cardiovascular magnetic resonance in constrictive pericardial disease. Cardiol Rev. 2009;17:77-82.
69. Karamitsos TD, Bull S, Francis JM, et al. Massive melanotic myocardial metastasis characterized by multiple cardiac imaging modalities. Int J Cardiol. 2011;146:e27-9.
70. Syed IS, Feng D, Harris SR, et al. Mr imaging of cardiac masses. Magn Reson Imaging Clin N Am. 2008;16:137-64. vii.
71. Kilner PJ, Geva T, Kaemmerer H, et al. Recommendations for cardiovascular magnetic resonance in adults with congenital heart disease from the respective working groups of the European society of cardiology. Eur Heart J. 2010;31:794-805.
72. Storkecky S, Suter TM. Insights into cardiovascular side-effects of modern anticancer therapeutics. Curr Opin Oncol. 2010;22:312-7.
73. Estep JD, Shah DJ, Nagueh SF, et al. The role of multimodality cardiac imaging in the transplanted heart. JACC Cardiovasc Imaging. 2009;2:1126-40.